Strata Critical Medical Lifts 2026 EBITDA Outlook to $33M-$35M
SRTA sits 56% above its 52-week low of $3.675.
Summary
Strata Critical Medical raised its 2026 adjusted EBITDA guidance to $33M-$35M, up from $29M-$33M, signaling stronger profitability expectations. This follows a series of strategic acquisitions in June, including a heart and lung transplant recovery program, which likely contributed to the improved outlook. The raise comes just days after Reuters reported Q2 revenue was expected to decline 5.3% year-over-year, making this EBITDA lift a notable positive surprise. The company's Q1 results showed an 87% revenue surge, and the new guidance suggests margin expansion or cost discipline is taking hold. With a market cap near $480M, the $4M midpoint increase is material and could shift earnings models. Q2 revenue rose 60.7% to $72.5M; net loss was $10.5M; adjusted EBITDA was $7.9M. 2026 revenue guidance was raised to $285-295M from $260-275M; free cash flow guidance was maintained at $15-22M.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Q2 revenue rose 60.7% to $72.5M; net loss was $10.5M; adjusted EBITDA was $7.9M. 2026 revenue guidance raised to $285-295M from $260-275M; free cash flow guidance maintained at $15-22M.
At the time of this announcement, SRTA was trading at $5.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $480.2M. The 52-week trading range was $3.68 to $6.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.